Trading Signals: TGTX Stock Price Prediction and Forecast (Mon. Aug. 10, 2015 - Wed. Sep. 14, 2022)(TG Therapeutics Inc)
| TGTX latest price $22.6200 (10.61%) ($20.0400 - $22.7800) on Tue. Jul. 7, 2020. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 6.54% (three month average) | RSI | 71 | Latest Price | $22.6200(10.61%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | TGTX advances 4.1% a day on average for past five trading days. | Weekly Trend | TGTX advances 5.3% a week on average for past two weeks. | Market Behavior | Broad based sell-off for large cap. Broad based sell-off for small cap. | Correlated ETFs | Broad market will support TGTX advance at 0% a week (0% probability) XBI(64%) ARKG(59%) ARKK(56%) IWO(56%) IBB(55%) | Factors Impacting TGTX price | TGTX will decline at least -3.27% in a week (0% probabilities). VIXM(-35%) VXX(-33%) UUP(-18%) DRIV(-4%) XLC(-2%) | Explanation | The rally is not sustainable and not supported by the broad market. | | | | | Relative Volatility | (options are extremely cheap) | | | Market Trend Strength | -3.27% (StdDev 6.54%) | Hourly BBV | 0 () | Intraday Trend | 12% | | | |
|
5 Day Moving Average | $20.59(9.86%) | 10 Day Moving Average | $19.72(14.71%) | 20 Day Moving Average | $18.98(19.18%) | To recent high | 0% | To recent low | 131.5% | Market Cap | $2.865b | | | | TG Therapeutics, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1101, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in New York, NY. |